Taro Pharmaceutical Industries (TARO) 20-F 2015 FY Annual report (foreign)

Exhibit 13

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT 2002

In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kal Sundaram, Chief Executive Officer and Director of the Company, and Michael Kalb, Group Vice President, Chief Financial Officer and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 30, 2015	By:	/s/ Kal Sundaram
		Kal Sundaram
		Chief Executive Officer and Director
	By:	/s/ Michael Kalb
		Michael Kalb
		Group Vice President, Chief Financial Officer and Chief Accounting Officer